ClinicalTrials.gg
CompletedNCT04207736Updated Nov 20, 2024Results posted

The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.

A Phase 3 interventional study of Reproxalap Ophthalmic Solution (0.25%) and Vehicle Ophthalmic Solution in Allergic Conjunctivitis, sponsored by Aldeyra Therapeutics, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-20.

Sponsored by Aldeyra Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Conjunctivitis, Allergic with a site in Canada — 2 open to participants now, 2 under way, none of them phase 3. Conjunctivitis, Allergic · Canada.

Enrollment
7th of 12
95 · median 98
Started
2019
the only one that year
Phase 3
6 of 14
none open now
Registered
9th of 14
by date
Lead sponsor
4 of 14
Aldeyra Therapeutics, Inc.

Among the 14 studies in Conjunctivitis, Allergic with a site in Canada, this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2019, is one of 6 in phase 3, and was the 9th registered.

Conjunctivitis, Allergic

211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.

Browse Conjunctivitis, Allergic studies →

Open to participants now

2 of the 14 studies in Conjunctivitis, Allergic with a site in Canada are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Conjunctivitis, Allergic with a site in Canada, or all of them as a file.
02

Study summary

The INVIGORATE Trial: A Randomized, Double-masked, Crossover Design, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.

Read the detailed description

The INVIGORATE Trial: A Randomized, Double-masked, Crossover Design, Vehicle-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Reproxalap Ophthalmic Solution (0.25%) Compared to Vehicle in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC).

03

Conditions studied

  • Allergic Conjunctivitis

Keywords

  • reproxalap
  • INVIGORATE
  • ADX-102
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • be at least 18 years of age of either gender and any race
  • have at least a two-year history of moderate-to-severe ragweed-induced allergic conjunctivitis based on principal investigator's judgement
  • have a positive skin prick test to ragweed pollen within the past year of screening

Exclusion criteria

Exclusion Criteria:

  • known or to any components of the product medication or components
  • history of uveitis, blepharitis, dry eye syndrome, herpes simplex keratitis, or herpes zoster keratitis;
  • presence of any ocular infection (bacterial, viral, or fungal) or active ocular inflammation (e.g., follicular conjunctivitis, allergic conjunctivitis) within 14 days prior to screening
  • presence of any chronic ocular degenerative condition or ocular inflammation that, in the opinion of the investigator, is likely to worsen over the course of the clinical trial;
  • diagnosis of moderate-to-severe pinguecula or pterygium (particularly if it results in chronic erythema), Stevens-Johnson Syndrome, ocular cicatricial pemphigoid, mucous membrane pemphigoid, significant conjunctival scarring, chemical burn, herpetic or neurotrophic keratitis, Cryopyrin Associated Periodic Syndrome (CAPS), or keratoconus
  • woman of who is pregnant or nursing
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
95 participants (actual)

Study arms

  • Active comparator
    Reproxalap Ophthalmic Solution (0.25%)

    Drug: Reproxalap Ophthalmic Solution (0.25%)

  • Placebo comparator
    Vehicle Ophthalmic Solution

    Drug: Vehicle Ophthalmic Solution

Interventions

  • Reproxalap Ophthalmic Solution (0.25%) dosed in the Environmental Exposure Chamber.

  • DrugVehicle Ophthalmic Solution

    Vehicle Ophthalmic Solution dosed in the Environmental Exposure Chamber.

06

What researchers measure

Primary outcomes

  1. Subject-Reported Ocular Itching Score Assessed Over 110 to 210 Minutes in the Allergy Chamber

    Change from baseline comparison of reproxalap to vehicle for ocular itching on a 0 to 4 scale ( 0 = none, 4 = severe). The treatment comparison was performed using a mixed model repeated measures approach for a crossover trial with two treatment periods. The model included time point, treatment, treatment period, treatment sequence, and interaction between time point and treatment as fixed effects, and subject nested within treatment sequence as a repeated measure.

    Time frame: The efficacy assessment period was 110 to 210 minutes in the allergy chamber; baseline was pre-Dose #1 for each treatment period.

Secondary outcomes

  1. Conjunctival Redness Score Assessed Over 12 to 212 Minutes in the Allergy Chamber

    Change from baseline comparison of reproxalap to vehicle for conjunctival redness on a 0 to 4 scale ( 0 = none, 4 = extremely severe). The treatment comparison was performed using a mixed model repeated measures approach for a crossover trial with two treatment periods. The model included time point, treatment, treatment period, treatment sequence, and interaction between time point and treatment as fixed effects, and subject nested within treatment sequence as a repeated measure.

    Time frame: The efficacy assessment period was 12 to 212 minutes in the allergy chamber; baseline was pre-Dose #1 for each treatment period.

07

Results

Posted Nov 20, 2024

Participant flow

Participant flow — Overall Study
MilestoneReproxalap (0.25%), Then VehicleVehicle, Then Reproxalap (0.25%)
Started4847
Completed4643
Not completed24

Outcome measures

PrimarySubject-Reported Ocular Itching Score Assessed Over 110 to 210 Minutes in the Allergy Chamber

Change from baseline comparison of reproxalap to vehicle for ocular itching on a 0 to 4 scale ( 0 = none, 4 = severe). The treatment comparison was performed using a mixed model repeated measures approach for a crossover trial with two treatment periods. The model included time point, treatment, treatment period, treatment sequence, and interaction between time point and treatment as fixed effects, and subject nested within treatment sequence as a repeated measure.

Time frame:
The efficacy assessment period was 110 to 210 minutes in the allergy chamber; baseline was pre-Dose #1 for each treatment period.
Reported as:
Least squares mean · score on a scale
Subject-Reported Ocular Itching Score Assessed Over 110 to 210 Minutes in the Allergy Chamber
score on a scaleReproxalap (0.25%)Vehicle
Subject-Reported Ocular Itching Score Assessed Over 110 to 210 Minutes in the Allergy Chamber0.94 ± 0.081.38 ± 0.08
SecondaryConjunctival Redness Score Assessed Over 12 to 212 Minutes in the Allergy Chamber

Change from baseline comparison of reproxalap to vehicle for conjunctival redness on a 0 to 4 scale ( 0 = none, 4 = extremely severe). The treatment comparison was performed using a mixed model repeated measures approach for a crossover trial with two treatment periods. The model included time point, treatment, treatment period, treatment sequence, and interaction between time point and treatment as fixed effects, and subject nested within treatment sequence as a repeated measure.

Time frame:
The efficacy assessment period was 12 to 212 minutes in the allergy chamber; baseline was pre-Dose #1 for each treatment period.
Reported as:
Least squares mean · score on a scale
Conjunctival Redness Score Assessed Over 12 to 212 Minutes in the Allergy Chamber
score on a scaleReproxalap (0.25%)Vehicle
Conjunctival Redness Score Assessed Over 12 to 212 Minutes in the Allergy Chamber0.51 ± 0.030.65 ± 0.03

Adverse events

Collected over The period of time over which adverse events were collected was approximately one day for each intervention.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Reproxalap (0.25%)0/91 (0%)0/91 (0%)69/91 (75.8%)
Vehicle0/93 (0%)0/93 (0%)6/93 (6.5%)
Most frequent other events
Most frequent other events
EventReproxalap (0.25%)Vehicle
General disorders and administrations site conditionsGeneral disorders68/916/93
Eye disodersEye disorders8/910/93

Baseline characteristics

Age, Continuous
Age, Continuous(years)Reproxalap (0.25%), Then VehicleVehicle, Then Reproxalap (0.25%)Total
Mean40.3 ± 13.4141.9 ± 11.1341.1 ± 12.29
Sex: Female, Male
Sex: Female, Male(Participants)Reproxalap (0.25%), Then VehicleVehicle, Then Reproxalap (0.25%)Total
Female262753
Male222042
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Reproxalap (0.25%), Then VehicleVehicle, Then Reproxalap (0.25%)Total
Hispanic or Latino426
Not Hispanic or Latino444589
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Reproxalap (0.25%), Then VehicleVehicle, Then Reproxalap (0.25%)Total
American Indian or Alaska Native000
Asian10717
Native Hawaiian or Other Pacific Islander000
Black or African American10919
White253055
More than one race314
Unknown or Not Reported000
08

Study locations

1 site
  • Cliantha Research
    Mississauga, Ontario, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Feb 2021, 14 months.

Results were first posted in Nov 2024, 3 years 9 months after primary completion. A results delay was requested in Jan 2022.

Of 21 phase 3 interventional studies under Conjunctivitis, Allergic, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 14 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2019
First posted
Dec 23, 2019
StartActual
Dec 5, 2019
Primary completionActual
Feb 16, 2021
CompletionActual
Feb 16, 2021
Results delay requested
Jan 3, 2022
Results first posted
Nov 20, 2024
Last update
Nov 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04207736
Responsible party
Sponsor
First posted
Dec 23, 2019
Start date
Dec 5, 2019
Primary completion
Feb 16, 2021
Completion
Feb 16, 2021
Results posted
Nov 20, 2024
Last update
Nov 20, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Reproxalap

Start the discussion